Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition
The German aerosol therapy company PARI Pharmaceuticals is spinning out a Phase III effort to develop a drug/device combo that matches an inhaled formulation of an immunosuppressant with a remotely monitored delivery device to treat a rare lung condition. And it’s recruited a trio of European venture groups, including Sofinnova Partners in Paris, to back a €43.5 million (about $46 million) round to boot it up to regulators on both sides of the Atlantic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.